The purpose of this study is to collect blood samples to determine the ability of a blood-based test that can be used able to identify lung cancers that may or may not also be seen on images of lungs.

COVID-19 Pneumonia is a viral pneumonia caused by the SARS-CoV-2 virus.
Umbilical cord derived mesencymal stromal cells (MSCs) are a form of stem cell (special human cells that are able to develop into many different cells types) that is derived from the placenta of a mother who has had a Caeserian Section. These cells are believed to suppress the body's immune response to the virus by changing the circulating inflammatory cells in the bloodstream. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia illness will be given 2 doses of MSCs at days 1 and 3 after consent. These MSC cells will be administered into a vein in your arm through an intravenous line and safety will be tested. How much oxygen a patient needs will be recorded over 90 days.

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response with agents targeting the RAAS improves clinical outcomes among patients with COVID-19.
Potential agents to investigate on this platform include TXA127 and TRV027. Both have potential beneficial effects on the RAAS system in COVID-19. We postulate that SARS-CoV-2 spike protein interaction with the ACE2 receptor leads to unchecked activity of AngII, and RAAS-targeting therapies will counterbalance pathologic RAAS effects. We will evaluate the efficacy of TXA127 and TRV027 in restoring RAAS balance.